Probiotic Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Probiotic Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Metabolically dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is an emerging chronic hepatic condition that is being diagnosed among 30-38% of adults worldwide, with prevalence in Europe reaching 25-30%. [Jurek Joanna Michalina (2026); evidence level 1]
• Under this updated framework, individuals previously classified as having NAFLD now fall within the MASLD definition, which replaces the earlier exclusionary criterion based solely on non-alcohol intake with broader cardiometabolic risk factors. [Jurek Joanna Michalina (2026); evidence level 1]
• The incidence of CHD rises with advancing age, with a notably increased risk observed in men aged 45 years or older and women aged 55 years or postmenopausal. [Zhong Yan (2026); evidence level 1]
• Hypertension, hyperlipidemia, and hyperglycemia are well-established as the three major modifiable risk factors for CHD. [Zhong Yan (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For probiotic blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Jurek Joanna Michalina (2026). Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020–2026). DOI: 10.3390/nu18101508. PMCID: PMC13209196. PMID: 42196968. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209196/
• Zhong Yan (2026). Effects of probiotics on blood lipids, glucose and pressure in patients with coronary heart disease: a systematic review and meta-analysis. DOI: 10.3389/fcvm.2026.1707408. PMCID: PMC12920485. PMID: 41725935. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12920485/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.